Government Schemes and Policy · 11 November 2026
Medical devices PLI scheme extended to 2035-36 as Centre eases investment and sales norms
Exam-focused facts from the 11 November 2026 current affairs briefing.
Key facts
- The Centre has extended the tenure of the Production Linked Incentive (PLI) scheme for medical device manufacturers by eight years, from 2027-28 to 2035-36, with the scheme's total outlay of Rs 3,420 crore remaining almost 80 per cent unutilised and approximately Rs 2,700 crore available for disbursement.
- Applicants across all segments will now have three years to set up their manufacturing facilities before the five-year performance period.
- The medical device industry under the scheme is divided into four segments: medical consumables, disposables and implants (TS1); critical components for manufacturing of medical devices (TS2); high-end devices whose domestic manufacturing is at a nascent stage (TS3); and high-end devices for which only assembly operations exist in India (TS4).
- The revised scheme has done away with the minimum sales threshold requirement, and companies now have to show a percentage annual growth over the base year instead of a fixed incremental growth in sales each year.
- Minimum investment thresholds have been relaxed: manufacturers with annual turnover of less than Rs 150 crore over the last three years must invest Rs 50 crore, while companies with higher turnover have no minimum requirement.
- For TS1 and TS3 products the investment must be in greenfield manufacturing facilities, for TS4 it can be for achieving higher value chain integration, and there is no minimum investment requirement for TS2.
- The revised guidelines have replaced the uniform sales-based flat incentive structure with a segment-specific tapered incentive rate, averaging about 5 per cent for TS1, about 9 per cent for TS2 and TS3, and 6 per cent for TS4.
- Applicants approved under the scheme prior to October 31 will continue to be governed by the previous set of guidelines.